Finerenone: A Pillar for the Treatment of Diabetic Kidney Disease

Bharat, Nathoo

doi:10.53941/ijctm.2025.100002

Open Access

Editorial

Finerenone: A Pillar for the Treatment of Diabetic Kidney Disease

Bharat Nathoo

Author Information

Submitted: 26 Jan 2025 | Accepted: 28 Jan 2025 | Published: 1 Mar 2025

Abstract

Diabetic kidney disease[DKD] has the potential to progress to end stage kidney disease as well as increase the risk of cardiovascular disease.. Remarkable advances have occurred in management of DKD., This review highlights the role of finerenone a novel nonsteroidal minerallocorticoid receptor antagonist in DKD.

References

1.

Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021—Results; Institute for Health Metrics and Evaluation: Seattle, WA, USA, 2024. Available online: https://vizhub.healthdata.org/gbd-results/ (accessed on 10 January 2025).

2.

Chertow, G.M.; Correa-Rotter, R.; Eckardt, K.U.; et al. Projecting the Clinical Burden of Chronic Kidney Disease at the Patient Level (INSIDE CKD): A Microsimulation Modelling Study. EClinicalMedicine 2024, 72, 102614.

3.

Aggarwal, R.; Ostrominski, J.W.; Vaduganathan, M. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011–2020. JAMA 2024, 331, 1858–1860.

4.

Rossing, P.; Caramori, M.L.; Chan, J.C.; et al. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022, 102 (Suppl. 5), S1–S127.

5.

Naaman, S.C.; Bakris, G.L. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care 2023, 46, 1574–1586.

6.

Tuttle, K.R.; Wong, L.; St. Peter, W.; et al. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clin. J. Am. Soc. Nephrol. 2022, 17, 1092–1103.

7.

Agarwal, R.; Kolkhof, P.; Bakris, G.; et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur. Heart J. 2021, 42, 152–161.

8.

Bakris, G.L.; Agarwal, R.; Chan, J.C.; et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA 2015, 314, 884–894.

9.

Bakris, G.L.; Agarwal, R.; Anker, S.D.; et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2020, 383, 2219–2229.

10.

Pitt, B.; Filippatos, G.; Agarwal, R.; et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N. Engl. J. Med. 2021, 385, 2252–2263.

11.

Agarwal, R.; Filippatos, G.; Pitt, B.; et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur. Heart J. 2022, 43, 474–484.

12.

Agarwal, R.; Joseph, A.; Anker, S.D.; et al. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J. Am. Soc. Nephrol. 2022, 33, 225–237.

13.

Vardeny, O.; Vaduganathan, M.; Claggett, B.L.; et al. Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiol. 2025, 10, 42–48.

14.

Green, J.B.; Mottl, A.K.; Bakris, G.; et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol. Dial. Transplant. 2023, 38, 894–903.

15.

Heerspink, H.J.L.; Agarwal, R.; Bakris, G.L.; et al. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrol. Dial. Transplant. 2024, 40, 308–319. https://doi.org/10.1093/ndt/gfae132.

16.

Heerspink, H.J.L.; Birkenfeld, A.L.; Cherney, D.Z.I.; et al. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res. Clin. Pract. 2023, 204, 110908.

17.

American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care 2025, 48 (Suppl. 1), S239–S251.

Share this article:

Download PDF

DOI

10.53941/ijctm.2025.100002

Issue

Volume 1, Issue 1

How to Cite

Nathoo, B. (2025). Finerenone: A Pillar for the Treatment of Diabetic Kidney Disease. International Journal of Clinical and Translational Medicine, 1(1), 2. https://doi.org/10.53941/ijctm.2025.100002

RIS

BibTex

Copyright & License

International Journal of Clinical and Translational Medicine

This work is licensed under a This work is licensed under a Creative Commons Attribution 4.0 International License.